Exchanges: NASDAQ | NYSE | XLON | AMS | ADS | TSE | BRU

Financial News Feed

BOSTON, May 23, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ: ALBO ), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that clinical data and important findings from studies of lead candidate odevixibat (A4250) in biliary atresia, Alagille syndrome and progressive familial intrahepatic cholestasis have been selected for presentation at the 52nd European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting, being held June 5-8, 2019, at the Scottish Event Campus in Glasgow, Scotland. Details of the presentations are as follows: Title: Effects of the ileal bile acid transport inhibitor A4250 on serum bile acids, pruritus and sleep in patients with Alagille syndrome: phase 2 study results Presentation Number: H-O-006 Session: Plenary Session: Hepatology Date / Time: Friday, June 7, 8:40-8:50 a.m. BST / 3:40-3:50 a.m. EST Presenter: Dr. Ulrich Baumann, Professor of Pediatric Gastroenterology and Hepatology, Hannover Medical School; Hannover, Germany Title: Development of …

Read more

ALBO earnings call for the period ending March 31, 2019.

Read more

– Initiation of Phase 2 clinical trial expected in Q2 2019 – – IBAT inhibition has potential to impact key markers of NASH – BOSTON, April 11, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ: ALBO ), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that its Investigational New Drug application (IND) has cleared the required 30 day review by the U.S. Food and Drug Administration and is in effect for a Phase 2 clinical trial of elobixibat, a first-in-class, once-daily, orally-available ileal bile acid transporter (IBAT) inhibitor, for the treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). "The IND and subsequent trial initiation are an important step for our NASH program, as we apply our expertise in bile acids and leverage our novel IBAT platform to address a large unmet medical need," said Ron Cooper, President and Chief Executive Officer of Albireo. "We have a two-pronged approach for NASH development: advancing elobixibat, a well-characterized IBAT inhibitor, into a Phase 2 trial and continuing to develop novel preclinical compounds." NAFLD affects about 25 percent of the world's population and is a major cause of liver disease.

Read more

Albireo Pharma, Inc. (:ALBO)’s shares are under review with key ownership changing hands of late. Investors may be looking ahead to the next couple of quarters trying to gauge whether the bulls will

Read more

BOSTON, April 01, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that mana

Read more

Narrowing in on shares of Albireo Pharma Inc (ALBO), we can see that the current 20-Day Bollinger Bands signal is currently reading Hold. This short-term indicator can be used to help identify oversol

Read more

Short-term trading can be extremely risky, though it can also be extremely lucrative. The term “short-term trading” is a trading strategy that can last for only a few minutes or last several days

Read more

Often times, investors are faced with challenging portfolio decisions. Maybe there are a few stocks that have outperformed expectations by a large margin. Investors may be hesitant to exit a position

Read more

Following some medium-term indicators on shares of Albireo Pharma Inc (ALBO), we can see that the 40-day commodity channel index signal is presently Buy. The CCI indicator is primarily used to spot ov

Read more

Monitoring the technical signals for Albireo Pharma Inc (ALBO), we have recently viewed the Percentage Price Oscillator Histogram line above zero. Traders may be using a PPOH reading above zero as a b

Read more

Equities analysts expect Albireo Pharma Inc (NASDAQ:ALBO) to report $1.65 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for

Read more

Albireo Pharma Inc (NASDAQ:ALBO) had an increase of 5.01% in short interest. ALBO’s SI was 555,500 shares in March as released by FINRA. Its up 5.01% from 529,000 shares previously. With 26,800 avg

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank